Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion–Positive Cancer
Zenocutuzumab showed efficacy in patients with advanced <i>NRG1</i> fusion-positive cancer, notably NSCLC and pancreatic cancer, with mainly low-grade adverse events. (Funded by Merus; eNRGy ClinicalTrials.gov number, NCT02912949.).
Authors
- Kim A. Reiss (ORCID: https://orcid.org/0000-0003-0774-9914)
- Jim Ford
- Cindy Neuzillet (ORCID: https://orcid.org/0000-0001-7037-7477)
- Frans L. Opdam (ORCID: https://orcid.org/0000-0002-9489-6535)
- Christoph Springfeld (ORCID: https://orcid.org/0000-0003-3843-101X)
- Grainne M. O’Kane (ORCID: https://orcid.org/0000-0002-8690-403X)
- James M. Cleary (ORCID: https://orcid.org/0000-0001-7213-3951)
- Sun Young Rha (ORCID: https://orcid.org/0000-0002-2512-4531)
- Jordi Rodón (ORCID: https://orcid.org/0000-0001-6467-3632)
- Lokesh Jain (ORCID: https://orcid.org/0000-0002-4790-7334)
- Kazumi Nishino (ORCID: https://orcid.org/0000-0003-2000-7472)
- Kōichi Goto (ORCID: https://orcid.org/0000-0002-3023-2510)
- Ernesto Wasserman
- M. Duruisseaux (ORCID: https://orcid.org/0000-0003-1495-0966)
- Stephen V. Liu (ORCID: https://orcid.org/0000-0002-4852-3914)
- Shola Adeyemi (ORCID: https://orcid.org/0000-0001-9317-5480)
- Viktoriya Stalbovskaya
- Emiliano Calvo (ORCID: https://orcid.org/0000-0003-4921-829X)
- Benjamin A. Weinberg (ORCID: https://orcid.org/0000-0002-0408-4817)
- Misako Nagasaka (ORCID: https://orcid.org/0000-0001-5308-615X)
- Kumiko Umemoto (ORCID: https://orcid.org/0000-0001-8901-7332)
- Alexander Edward Dela Cruz Drilon (ORCID: https://orcid.org/0000-0001-6806-9061)
- Tanios Bekaii‐Saab (ORCID: https://orcid.org/0000-0001-7721-1699)
- Eileen Mary O'Reilly (ORCID: https://orcid.org/0000-0002-8076-9199)
- Teresa Macarulla (ORCID: https://orcid.org/0000-0002-5856-4082)
- Shekeab Jauhari (ORCID: https://orcid.org/0000-0001-7484-1214)
- Antoine Hollebecque (ORCID: https://orcid.org/0000-0003-2869-7551)
- Sai‐Hong Ignatius Ou (ORCID: https://orcid.org/0000-0002-1764-4975)
- Alison M. Schram (ORCID: https://orcid.org/0000-0002-6070-2413)
- Joon Oh Park
- Dong-Wan Kim
- Andrew K. Joe
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Hebron University (PS)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- Inserm (FR)
- St. Marianna University School of Medicine (JP)
- Georgetown University (US)
- University of California, Irvine (US)
- Cornell University (US)
- Heidelberg University (DE)
- Georgetown University Medical Center (US)
- Institut Gustave Roussy (FR)
- University Hospital Heidelberg (DE)
- Samsung Medical Center (KR)
- Princess Margaret Cancer Centre (CA)
- Seoul National University Hospital (KR)
- The Netherlands Cancer Institute (NL)
- Hospices Civils de Lyon (FR)
- National Center for Tumor Diseases (DE)
- Dana-Farber Cancer Institute (US)
- South Texas Accelerated Research Therapeutics (US)
- Centre de Recherche en Cancérologie de Lyon (FR)
- Mayo Clinic Hospital (US)
- Merus (Netherlands) (NL)
- Hôpital Louis Pradel (FR)
- National Cancer Center Hospital East (JP)
- Osaka International Cancer Institute (JP)
- Yonsei University Health System (KR)
- Vall d'Hebron Institute of Oncology (ES)
- University of Pennsylvania (US)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-02-05
- DOI
- https://doi.org/10.1056/nejmoa2405008
- Citations
- 91
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 123.23